-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A better understanding of the molecular biology of renal cell carcinoma (RCC) can lead to the substantial development of treatment options.
The VHL gene is lost in approximately 90% of ccRCC tumors.
Blood vessel
Hypoxia-inducible factor-2α (HIF-2α) is a transcription factor that often accumulates in clear cell renal cell carcinoma (ccRCC), resulting in the constitutive activation of genes involved in carcinogenesis.
Belzutifan (MK-6482, formerly known as PT2977) is a potent and selective HIF-2α small molecule inhibitor.
Efficacy outcome of the ccRCC cohort
Efficacy outcome of the ccRCC cohortIn the dose-escalation cohort (n = 43), no dose-limiting toxicity occurred and the maximum tolerated dose was not reached when the dose reached 160 mg once a day; RP2D was 120 mg once a day.
A decrease in plasma erythropoietin was observed at all doses; the concentration of erythropoietin correlated with the plasma concentration of belsutifan.
The objective response rate was 25% (all partial responses), and the median progression-free survival was 14.
Belzutifan was well tolerated and showed preliminary antitumor activity in a large number of pretreated patients.
Original source:
Original source:Toni K.
Toni K.
Leave a message here